BiochemProbe — Life Science Research Reagents

Paltusotine free base · Synonyms: CRN00808

Paltusotine is an orally active, nonpeptide selective somatostatin type 2 receptor agonist.

For research use only. Not for human or veterinary use.

Target Amyloid-β
Research area Neurological Disease
Purity >98% Stock Inquire

Paltusotine structure

CAS No.: 2172870-89-0

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 380.00 BP-01984-100mg In stock Get quote
250 mg USD 645.00 BP-01984-250mg In stock Get quote
500 mg USD 968.00 BP-01984-500mg In stock Get quote
1 g USD 1,450.00 BP-01984-1g In stock Get quote

Need another size or custom synthesis? Request a quote.

Description

Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.

Biological activity

ALZ-801 (oral administration; 172?mg/kg; single dose) exhibits mean AUCt values of 58,758 and? 5841 ng/ml.h in plasma and brain, respectively. The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice

Identifiers

SMILES
N#CC1=C(O)C(C2=CC3=C(N4CCC(CC4)N)C(C5=CC(F)=CC(F)=C5)=CN=C3C=C2)=CC=C1
InChIKey
GHILNKWBALQPDP-UHFFFAOYSA-N

Specifications

MW (average)
456.4866
Formula
C27H22F2N4O
CAS No.
2172870-89-0
Physical state
Solid
Color
white to yellow
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
4°C, sealed storage, away from moisture

Solubility

Soluble in H2O : 30 mg/mL

References

[1]. Murray B. Gordon, et al. Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy. Endocrine Abstracts (2021) 73 OC15.4.
[2]. Rosa Luo, et al. Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, A

Same target

Search Amyloid-β

Same research area

Search Neurological Disease